Zevra Therapeutics, Inc.

ZVRA

CIK 0001434647 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$34M
↑+183.4% +$22Mvs FY2024 (Q4)
Operating Income
$9M
Net Income
$7M
Gross Profit
$33M
↑+205.4% +$22Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
67/100
  • Profitability
    0ROIC -38.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.68 (above 1.5 = solid)
  • Leverage
    80D/E 0.40 (under 0.5 = conservative)
  • Efficiency
    20Asset Turnover 0.46x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +183.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 15.9% · trend +529.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$866K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$13M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$285M
everything owned
Total liabilities
$130M
everything owed
Stockholders' equity
$155M
shareholder claim
Net debt
$-478K
Net cash position ($478K)

Recent performance · 49 quarters

Revenue↑+183.4% +$22M
$34M
Net Income
$12M
Free Cash Flow
$6M
Operating Margin↑+754.9pts
15.9%

Drill down